What is RDAtrademark?

RNA Disruption Assay (RDA™) is a diagnostic test  that measures tumor response to treatment early during neoadjuvant chemotherapy. RDA is a useful tool for managing response-guided therapy. RDA consists of proprietary methods that quantify ribosomal RNA (rRNA) disruption induced by a spectrum of chemotherapeutic and targeted drugs. Core or fine needle aspirate tumor biopsies are taken as early as day 14 following the first cycle of chemotherapy.
RDA will make possible
an adaptation of treatment
in real time
RDA stratifies patients into 3 response zones. Response zone 1 is characterized by a low level of RNA disruption, indicating an ineffective chemotherapy response, and a low likelihood of pathologic Complete Response (pCR) or enhanced disease free survival. Response zone 2 indicates an intermediate response. Response zone 3, with a high level of RNA disruption, indicates a higher likelihood to achieve a pCR and enhanced disease free survival.

How does RDAtrademark work?

A strong association between rRNA disruption and chemotherapy response has been demonstrated in preclinical and clinical studies. Equally important, insufficient RNA disruption is associated with unresponsiveness to chemotherapy and poor prognosis. Tumor RNA disruption by drugs is dependent on the individual’s tumor biology irrespective of breast cancer subtype. In the clinical trial (NCIC-CTG,MA.22), patients with low and moderate RNA disruption, zone 1 and 2, were at much higher risk for disease progression compared to patients with a high level of RNA disruption, RDA response zone 3.
RDA™ will offer significant benefits for your patients, and for healthcare systems.

  • Patients avoid ineffective toxic treatment and can be switched to alternate treatments that may improve their survival.
  • Physicians have an objective tool to personalize treatment for each patient.
  • Healthcare payers avoid the substantial costs of ineffective treatment.

How will RDA be applied in Clinical Practice?

FNA or core tumor biopsies are obtained as early as 14 days after initiation of chemotherapy. To account for tumor heterogeneity, two biopsies are taken. Immediately after obtaining the sample, the specimen is placed in an RNA fixative and sent to Rna Diagnostics.

Read what Dr. Bryan Hennessy has to say about RDA

Dr. Bryan Hennessy

“RDA is an exciting new technology that addresses a serious unmet need. With RDA testing we will be able to tailor treatment to actual patient response. We are very interested in exploring how RDA can help us improve treatments for both breast cancer and rectal cancer patients.”

Dr. Bryan Hennessy, Consultant Medical Oncologist, Beaumont Hospital, Dublin and Our Lady of Lourdes Hospital, Drogheda, Senior Lecturer, Royal College of Surgeons in Ireland (RCSI), Adjunct Professor at The University of Texas MD Anderson Cancer Center and Dublin City University (DCU), Vice Chair of ICORG, the Irish Clinical Oncology Research Group.

Rna Diagnostics is collaborating with research centers around the world.

Scientific publications and research

For further information or for collaborations in clinical trials, please contact:
Sanaa Noubir – Director of Clinical Development
snoubir@rnadiagnostics.com

The Chemo Response Company